Dryocrassin ABBA ameliorates Streptococcus pneumoniae-induced infection in vitro through inhibiting Streptococcus pneumoniae growth and neutralizing pneumolysin activity.

Abstract

To explore the role of dryocrassin ABBA (ABBA) in the prevention and treatment of Streptococcus pneumoniae (S. pneumoniae) infections in vitro, a minimal inhibitory concentration test, growth curve assay, hemolysis assay, BacLight LIVE/DEAD staining experiments, oligomerization inhibition assay, time-killing test, LDH release detection assay and cytotoxicity test were performed to evaluate the efficacy of ABBA against S. pneumoniae infections in vitro. The results indicated that ABBA treatment exists bactericidal effect on S. pneumoniae at a concentration of less than 8 μg/ml. Furthermore, ABBA was effective at inhibiting the oligomerization of pneumolysin (PLY) from reducing its hemolytic activity. Meanwhile, ABBA could ameliorate cell injury by neutralizing the biological activity of PLY without cytotoxicity. In summary, ABBA was a leading compound against S. pneumoniae infections through bactericidal effect and neutralizing PLY activity.

• Authors: Hongfa Lv, Tianqi Fang, Fanrong Kong, Jianfeng Wang, Xuming Deng, Qinlei Yu, Meiyang Sun, Xiaoying Liang
• Journal: Microbial pathogenesis (Microb Pathog) Vol. 150 Pg. 104683 (Jan 2021) ISSN: 1096-1208 [Electronic] England
• PMID: 33309685 (Publication Type: Journal Article)
• Copyright: Copyright © 2020 Elsevier Ltd. All rights reserved.

Chemical References

• Bacterial Proteins
• Benzylidene Compounds
• Cyclohexanones
• Streptolysins
• plY protein, Streptococcus pneumoniae
• dryocrassin

Topics

• Bacterial Proteins
• Benzylidene Compounds
• Cyclohexanones
• Humans
• Pneumococcal Infections (drug therapy)
• Streptococcus pneumoniae
• Streptolysins